Hims & Hers Health Inc. (HIMS) 今日盘中股价大幅下跌5.10%，引起了市场的广泛关注。
消息面上，此次股价波动主要与丹麦制药巨头诺和诺德对其提起的专利侵权诉讼有关。诺和诺德周一提起诉讼，指控Hims公司销售其减肥药Wegovy（活性成分为司美格鲁肽）的仿制品，侵犯了其专利权。与此同时，美国食品药品管理局（FDA）已警告将对GLP-1类复合药物采取执法行动，Hims公司随后下架了其售价49美元的复合司美格鲁肽产品。
这起诉讼标志着诺和诺德在打击其重磅药物仿制品方面开辟了新战线。分析指出，专利诉讼通常耗时较长且可能导致高额赔偿，这引发了市场对Hims公司潜在法律风险及未来业务发展的担忧，从而打压了股价。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.